AI-Driven Microbiome Profiling for Precision Management of Inflammatory Bowel Disease

Inflammatory bowel disease, or IBD, comprises crohn’s disease and
ulcerative colitis, chronic inflammatory disorders mediated by
alterations in the human microbiome. Recent studies indicate that
imbalance in the microbiome significantly contributes to disease
severity and treatment response in IBD patients. In the current era
of next-generation sequencing and other omics-based approaches,
artificial intelligence, or AI, has been successfully applied to analyze
the human microbiome data to identify specific microbial patterns to
aid in the diagnosis of IBD, disease classification, and prediction of
treatment outcomes. In addition, non-invasive biomarker discovery
through stool samples of affected individuals can be achieved, thus
enabling a more precise approach to disease management in IBD
patients.